GENinCode (LON:GENI) Stock Price Up 6% – Here’s Why

Shares of GENinCode Plc (LON:GENI) shot up 6% during trading on Friday . The stock traded as high as GBX 1.25 and last traded at GBX 1.01. 24,361,582 shares traded hands during trading, an increase of 354% from the average session volume of 5,363,759 shares. The stock had previously closed at GBX 0.95.

GENinCode Stock Performance

The company has a debt-to-equity ratio of 117.74, a quick ratio of 15.88 and a current ratio of 0.93. The company has a market cap of £7.58 million, a PE ratio of -0.48 and a beta of 0.56. The business’s 50-day moving average is GBX 0.86 and its 200 day moving average is GBX 1.02.

GENinCode (LON:GENI) last posted its quarterly earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. The business had revenue of GBX 308 million for the quarter. On average, equities research analysts predict that GENinCode Plc will post -7.1299999 EPS for the current fiscal year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.